Remdesivir close to authorisation for COVID-19 treatment
BRUSSELS: The head of the European Union’s medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead’s remdesivir as a COVID-19 treatment could be granted in coming days.
The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised.
Also read: At-home COVID-19 nasal swab test kit gets FDA nod
Authorisation soon
“It might be that a conditional market authorisation can be issued in the coming days,” Rasi told a hearing in the EU Parliament in Brussels.
Apart from remdesivir, Rasi said other possible treatments against COVID-19 that may be available fast are those based on monoclonal antibodies, which can “neutralize” the new coronavirus (SARS-CoV-2) that causes the illness COVID-19
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
